XFOR Stock Analysis: Buy, Sell, or Hold?
XFOR - X4 Pharmaceuticals, Inc. Common Stock
$4.05
-0.36 (-8.16%)
▼
5d:
+0.5%
30d:
+8.58%
90d:
-1.22%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 14, 2026
30d
Get Alerted When XFOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: XFOR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: XFOR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: XFOR is currently trading at $4.05, which is considered fair relative to its 30-day fair value range of $3.85 to $4.23.
Technical Outlook: Technically, XFOR is in a uptrend. Immediate support is located at $3.66, while resistance sits at $4.36. Short-term momentum is weak, with the stock down 8.2% recently.
Market Sentiment: XFOR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (81th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $11.60 (+186.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, XFOR is in a uptrend. Immediate support is located at $3.66, while resistance sits at $4.36. Short-term momentum is weak, with the stock down 8.2% recently.
Market Sentiment: XFOR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (81th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $11.60 (+186.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.85 -
$4.23
Company Quality Score
62/100
(BUY)
Options IV Signal
81th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
64.6%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Options expensive (IV 81th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.2%)
- BULLISH: Trading 186.4% below Wall St target ($11.60)
Trading Range Analysis
30-Day Trading Range
$3.85 -
$4.23
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$1.56
(38.5%)
Support & Resistance Levels
Support Level
$3.66
Resistance Level
$4.36
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.94
Wall Street Target
$11.60
(+186.4%)
Revenue Growth (YoY)
-90.6%
Share & Embed Analysis
Last updated: July 13, 2026 8:43 PM ET
Data refreshes hourly during market hours. Next update: 9:43 PM
Data refreshes hourly during market hours. Next update: 9:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XFOR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 57 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 60 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 57 HOLD |
